Swetter SM, Johnson D, Albertini MR, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024. Accessed August 30, 2024. To view the most recent version, visit https://www.nccn.org

• PubMed
Swetter SM, Johnson D, Albertini MR, NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024. Accessed August 30, 2024. To view the most recent version, visit https://www.nccn.org)| false
• Export Citation

Michielin O, van Akkooi ACJ, Ascierto PA, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1884–1901.

• PubMed
Michielin O, van Akkooi ACJ, Ascierto PA, Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1884–1901.)| false
• Search Google Scholar
• Export Citation

Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019. Eur J Cancer 2020;126:159–177.

• PubMed
Garbe C, Amaral T, Peris K, European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019. Eur J Cancer 2020;126:159–177.)| false
• Search Google Scholar
• Export Citation

Sladden MJ, Nieweg OE, Howle J, et al. Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma. Med J Aust 2018;208:137–142.

• PubMed
Sladden MJ, Nieweg OE, Howle J, Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma. Med J Aust 2018;208:137–142.)| false
• Search Google Scholar
• Export Citation

Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 2001;8:101–108.

• PubMed
Balch CM, Soong SJ, Smith T, Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 2001;8:101–108.)| false
• Search Google Scholar
• Export Citation

Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011;378:1635–1642.

• PubMed
Gillgren P, Drzewiecki KT, Niin M, 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011;378:1635–1642.)| false
• Search Google Scholar
• Export Citation

Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757–766.

• PubMed
Thomas JM, Newton-Bishop J, A’Hern R, Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757–766.)| false
• Search Google Scholar
• Export Citation

Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol 2016;17:184–192.

• PubMed
Hayes AJ, Maynard L, Coombes G, Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol 2016;17:184–192.)| false
• Search Google Scholar
• Export Citation

Utjés D, Malmstedt J, Teras J, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet 2019;394:471–477.

• PubMed
Utjés D, Malmstedt J, Teras J, 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet 2019;394:471–477.)| false
• Search Google Scholar
• Export Citation

Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984;200:759–763.

• PubMed
Kelly JW, Sagebiel RW, Calderon W, The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984;200:759–763.)| false
• Search Google Scholar
• Export Citation

Niebling MG, Haydu LE, Lo SN, et al. The prognostic significance of microsatellites in cutaneous melanoma. Mod Pathol 2020;33:1369–1379.

• PubMed
Niebling MG, Haydu LE, Lo SN, The prognostic significance of microsatellites in cutaneous melanoma. Mod Pathol 2020;33:1369–1379.)| false
• Search Google Scholar
• Export Citation

Kimsey TF, Cohen T, Patel A, et al. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol 2009;16:1176–1183.

• PubMed
Kimsey TF, Cohen T, Patel A, Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol 2009;16:1176–1183.)| false
• Search Google Scholar
• Export Citation

Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:1465–1477.

• PubMed
Ascierto PA, Del Vecchio M, Mandalá M, Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:1465–1477.)| false
• Search Google Scholar
• Export Citation

Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020;6:519–527.

• PubMed
Eggermont AMM, Kicinski M, Blank CU, Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020;6:519–527.)| false
• Search Google Scholar
• Export Citation

Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383:1139–1148.

• PubMed
Dummer R, Hauschild A, Santinami M, Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383:1139–1148.)| false
• Search Google Scholar
• Export Citation

Dummer R, Brase JC, Garrett J, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol 2020;21:358–372.

• PubMed
Dummer R, Brase JC, Garrett J, Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF^V600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol 2020;21:358–372.)| false
• Search Google Scholar
• Export Citation

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol 2021;39(Suppl):Abstract 9506.

• PubMed
Wolchok JD, Chiarion-Sileni V, Gonzalez R, CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol 2021;39(Suppl):Abstract 9506.)| false
• Search Google Scholar
• Export Citation

Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019;20:1239–1251.

• PubMed
Robert C, Ribas A, Schachter J, Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019;20:1239–1251.)| false
• Search Google Scholar
• Export Citation

Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381:626–636.

• PubMed
Robert C, Grob JJ, Stroyakovskiy D, Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381:626–636.)| false
• Search Google Scholar
• Export Citation

Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395:1835–1844.

• PubMed
Gutzmer R, Stroyakovskiy D, Gogas H, Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF^V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395:1835–1844.)| false
• Search Google Scholar
• Export Citation

Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol 2020;38:3947–3970.

• PubMed
Seth R, Messersmith H, Kaur V, Systemic therapy for melanoma: ASCO guideline. J Clin Oncol 2020;38:3947–3970.)| false
• Search Google Scholar
• Export Citation

Luke JJ, Ascierto PA, Carlino MS, et al. KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol 2020;16:4429–4438.

• PubMed
Luke JJ, Ascierto PA, Carlino MS, KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol 2020;16:4429–4438.)| false
• Search Google Scholar
• Export Citation

Zijlker LP, Eggermont AMM, van Akkooi ACJ. The end of wide local excision (WLE) margins for melanoma? Eur J Cancer 2023;178:82–87.

• PubMed
Zijlker LP, Eggermont AMM, van Akkooi ACJ. The end of wide local excision (WLE) margins for melanoma? Eur J Cancer 2023;178:82–87.)| false
• Search Google Scholar
• Export Citation

Frishberg DP, Balch C, Balzer BL, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 2009;133:1560–1567.

• PubMed
Frishberg DP, Balch C, Balzer BL, Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 2009;133:1560–1567.)| false
• Search Google Scholar
• Export Citation

Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin. In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual, 8th ed. Springer; 2017:563–585.

• PubMed
Gershenwald JE, Scolyer RA, Hess KR, Melanoma of the skin. In: Amin MB, Edge SB, Greene FL, , eds. AJCC Cancer Staging Manual, 8th ed. Springer; 2017:563–585.)| false
• Search Google Scholar
• Export Citation

Houghton AN, Bloomer WD, Chu D, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 1.2000. To view the most recent version, visit https://www.nccn.org

• PubMed
Houghton AN, Bloomer WD, Chu D, NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 1.2000. To view the most recent version, visit https://www.nccn.org)| false
• Export Citation

Houghton AN, Bloomer WD, Chu D, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 1.2002. To view the most recent version, visit https://www.nccn.org

• PubMed
Houghton AN, Bloomer WD, Chu D, NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 1.2002. To view the most recent version, visit https://www.nccn.org)| false
• Export Citation

Coit DG, Andtbacka R, Bichakjian CK, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2009. To view the most recent version, visit https://www.nccn.org

• PubMed
Coit DG, Andtbacka R, Bichakjian CK, NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2009. To view the most recent version, visit https://www.nccn.org)| false
• Export Citation

Coit DG, Thompson JA, Albertini MR, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 3.2018. To view the most recent version, visit https://www.nccn.org

• PubMed
Coit DG, Thompson JA, Albertini MR, NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 3.2018. To view the most recent version, visit https://www.nccn.org)| false
• Export Citation

Flury BK, Riedwyl H. Standard distance in univariate and multivariate analysis. Am Stat 1986;40:249–251.

• PubMed
Flury BK, Riedwyl H. Standard distance in univariate and multivariate analysis. Am Stat 1986;40:249–251.)| false
• Search Google Scholar
• Export Citation

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661–3679.

• PubMed
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661–3679.)| false
• Search Google Scholar
• Export Citation

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.

• PubMed
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.)| false
• Search Google Scholar
• Export Citation

Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551–561.

• PubMed
Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551–561.)| false
• Search Google Scholar
• Export Citation

Jackett LA, Satgunaseelan L, Roper E, et al. Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas. Pathology 2022;54:71–78.

• PubMed
Jackett LA, Satgunaseelan L, Roper E, Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas. Pathology 2022;54:71–78.)| false
• Search Google Scholar
• Export Citation

Namin AW, Welby L, Baker AT, Dooley LM. Positive margins in cutaneous melanoma of the head and neck: implications for timing of reconstruction. Otolaryngol Head Neck Surg 2021;164:1052–1057.

• PubMed
Namin AW, Welby L, Baker AT, Dooley LM. Positive margins in cutaneous melanoma of the head and neck: implications for timing of reconstruction. Otolaryngol Head Neck Surg 2021;164:1052–1057.)| false
• Search Google Scholar
• Export Citation

Rawlani R, Rawlani V, Qureshi HA, et al. Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol 2015;111:795–799.

• PubMed
Rawlani R, Rawlani V, Qureshi HA, Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol 2015;111:795–799.)| false
• Search Google Scholar
• Export Citation

Hunger RE, Angermeier S, Seyed Jafari SM, et al. A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. J Am Acad Dermatol 2015;72:1054–1059.

• PubMed
Hunger RE, Angermeier S, Seyed Jafari SM, A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. J Am Acad Dermatol 2015;72:1054–1059.)| false
• Search Google Scholar
• Export Citation

Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg 2013;258:152–157.

• PubMed
Pasquali S, Haydu LE, Scolyer RA, The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg 2013;258:152–157.)| false
• Search Google Scholar
• Export Citation

Hanna S, Lo SN, Saw RP. Surgical excision margins in primary cutaneous melanoma: a systematic review and meta-analysis. Eur J Surg Oncol 2021;47:1558–1574.

• PubMed
Hanna S, Lo SN, Saw RP. Surgical excision margins in primary cutaneous melanoma: a systematic review and meta-analysis. Eur J Surg Oncol 2021;47:1558–1574.)| false
• Search Google Scholar
• Export Citation

Pandya R, Basra M, Twohig E, et al. Can we reduce excision margins for head and neck melanoma? A 12-year retrospective study. Br J Oral Maxillofac Surg 2022;60:134–139.

• PubMed
Pandya R, Basra M, Twohig E, Can we reduce excision margins for head and neck melanoma? A 12-year retrospective study. Br J Oral Maxillofac Surg 2022;60:134–139.)| false
• Search Google Scholar
• Export Citation

Ruskin O, Sanelli A, Herschtal A, et al. Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: a retrospective analysis. Head Neck 2016;38:1373–1379.

• PubMed
Ruskin O, Sanelli A, Herschtal A, Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: a retrospective analysis. Head Neck 2016;38:1373–1379.)| false
• Search Google Scholar
• Export Citation

Moncrieff MD, Gyorki D, Saw R, et al. 1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study. Ann Surg Oncol 2018;25:2541–2549.

• PubMed
Moncrieff MD, Gyorki D, Saw R, 1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study. Ann Surg Oncol 2018;25:2541–2549.)| false
• Search Google Scholar
• Export Citation

Rossi AJ, Verbus EA, Faries MB, et al. A phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II). Ann Surg Oncol. Published online April 22, 2022. doi:10.1245/s10434-022-11766-z

• PubMed
Rossi AJ, Verbus EA, Faries MB, A phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II). Ann Surg Oncol. Published online April 22, 2022. doi:10.1245/s10434-022-11766-z)| false
• Search Google Scholar
• Export Citation